KVUE

What You Should Know

Kenvue Inc. is the world's largest pure-play consumer-health company by revenue, spun off from Johnson & Johnson in 2023, organized into three reporting segments: Self Care (the largest and highest-margin segment, including Tylenol pain relief, Motrin, Sudafed, Benadryl, Zyrtec, Pepcid, Imodium, Nicorette smoking-cessation products, and the cough-cold-and-allergy portfolio), Skin Health and Beauty (Neutrogena, Aveeno, OGX, Clean & Clear, and other skin-care and beauty brands), and Essential Health (Band-Aid wound care, Listerine oral care, Johnson's baby-care products, Aveeno baby, Desitin, Tylenol-and-children's brands, and Carefree/Stayfree feminine care). Consumer-health, over-the-counter-medicine, skin-care, oral-care, and baby-care manufacturing is unambiguously permissible at the activity level under standard Sharia methodology — Kenvue's products serve essential personal-health and hygiene needs. The financial screen consideration is leverage: Kenvue took on debt at the time of its J&J separation; the consolidated debt-to-market-cap ratio sits in a manageable range that should be verified against the 33% Sharia threshold at the time of investment. Most major Sharia advisory boards classify Kenvue as permissible with purification of small interest-income components.